Oportuzumab monatox
Oportuzumab Monatox
Oportuzumab Monatox (pronunciation: oh-por-tuh-zoo-mab mon-a-tox) is a biologic therapy used in the treatment of non-muscle invasive bladder cancer (NMIBC). It is also known by its brand name, Vicinium.
Etymology
The name Oportuzumab Monatox is derived from the combination of two components: Oportuzumab, a monoclonal antibody that targets the protein EpCAM found on the surface of bladder cancer cells, and Monatox, a derivative of the Pseudomonas aeruginosa bacterial toxin.
Usage
Oportuzumab Monatox is used for the treatment of BCG-unresponsive, high-grade NMIBC in patients who have previously received a minimum of two courses of Bacillus Calmette-Guérin (BCG) and who are ineligible for or have elected not to undergo cystectomy.
Mechanism of Action
Oportuzumab Monatox works by binding to the EpCAM protein on the surface of bladder cancer cells. Once bound, the toxin component of the drug is internalized by the cancer cell, inhibiting protein synthesis and leading to cell death.
Related Terms
- EpCAM
- Pseudomonas aeruginosa
- Bacillus Calmette-Guérin
- Cystectomy
- Non-muscle invasive bladder cancer
- Monoclonal antibody
- Biologic therapy
External links
- Medical encyclopedia article on Oportuzumab monatox
- Wikipedia's article - Oportuzumab monatox
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski